Sona Nanotech Initiates Early Feasibility Study for Targeted Hyperthermia Therapy

Sona Nanotech Inc has dosed the first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment, which aims to modify tumors making them more visible to the immune system, thereby enabling an elimination of the cancer. The study will evaluate the safety, tolerability, and preliminary efficacy of THT in patients with advanced melanoma who have not responded to standard immunotherapy treatments. The trial will monitor participants for treatment tolerability, adverse events, clinical response, and pathological immune response directly linked to the therapy.

Key Takeaways:

• The study will involve two treatments administered one week apart and will assess tumor growth inhibition and immune system engagement.
• THT may offer advantages over existing immunotherapy approaches, which often have limited effectiveness and side effects.
• The study will provide insights into the effect of THT in human cancer, and success will enable Sona Nanotech to proceed to a more critical study that will evaluate the biological effects and clinical outcomes of this technology.
• The company plans to follow this study with a second, more expansive human trial, and will publish their findings in a peer-reviewed article in a leading scientific journal.
• This study has the potential to inform on THT's potential for complementing the treatment of other cancer types.

Statistics:

• The study involves two treatments administered one week apart.
• The study will monitor 100 patients with advanced melanoma who have not responded to standard immunotherapy treatments.
• The company expects initial results in the summer, with final results anticipated in the fall.
• Sona Nanotech has conducted multiple preclinical studies on THT, which has led to this critical first clinical step.
• The company plans to engage with regulators further to inform on the potential of THT as a cancer treatment.

Sources:

• Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) press release, April 2023.
• Sona Nanotech Inc website, citing company statement.